Loading institutional data...
Loading institutional data...
Held by 429 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| MASI | — | — | — | — | 9.4% | 61.9% | -9.9% | -21.0% | -12.2% | 1.5× | 429 |
Peers = companies sharing MASI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.53B 100.0% | $1.40B 100.0% | $1.28B 100.0% | $2.04B 100.0% | $1.24B 100.0% | $1.14B 100.0% | $937.8M 100.0% | $858.3M 100.0% | $790.2M 100.0% | $712.9M 100.0% |
| Cost of Revenue | $581.7M 38.1% | $600.9M 43.1% | $509.9M 40.0% | $977.0M 48.0% | $430.8M 34.8% | $400.7M 35.0% | $308.7M 32.9% | $283.4M 33.0% | $268.2M 33.9% | $234.6M 32.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $263.0M 33.3% | $230.8M 32.4% |
| Gross Profit | $945.2M 61.9% | $794.3M 56.9% | $765.6M 60.0% | $1.06B 52.0% | $808.4M 65.2% | $743.0M 65.0% | $629.2M 67.1% | $574.9M 67.0% | $522.0M 66.1% | $478.3M 67.1% |
| Research & Development | $126.4M 8.3% | $182.2M 13.1% | $130.5M 10.2% | $191.4M 9.4% | $137.2M 11.1% | $118.7M 10.4% | $93.3M 9.9% | $81.0M 9.4% | $65.2M 8.3% | $57.7M 8.1% |
| Selling, General & Admin | $506.0M 33.1% | $548.6M 39.3% | $451.3M 35.4% | $657.4M 32.3% | $395.4M 31.9% | $369.0M 32.3% | $314.7M 33.6% | $285.4M 33.3% | $273.0M 34.5% | $254.7M 35.7% |
| Total Operating Expenses | $635.2M 41.6% | $731.3M 52.4% | $599.6M 47.0% | $848.8M 41.7% | $532.6M 43.0% | $487.2M 42.6% | $408.0M 43.5% | $366.8M 42.7% | $338.2M 42.8% | $42.4M 5.9% |
| Operating Income | $310.0M 20.3% | $63.0M 4.5% | $166.0M 13.0% | $210.0M 10.3% | $275.8M 22.3% | $255.8M 22.4% | $221.2M 23.6% | $208.0M 24.2% | $183.8M 23.3% | $435.9M 61.2% |
| Interest Expense | $33.2M 2.2% | $41.2M 3.0% | $50.3M 3.9% | $25.7M 1.3% | $300K 0.0% | $300K 0.0% | $328K 0.0% | $706K 0.1% | $678K 0.1% | $3.3M 0.5% |
| Interest & Investment Income | $3.4M 0.2% | $4.4M 0.3% | $2.9M 0.2% | $1.8M 0.1% | $900K 0.1% | $5.5M 0.5% | $13.9M 1.5% | $8.2M 1.0% | $3.0M 0.4% | -$464K -0.1% |
| Other Income (Expense), net | -$37.4M -2.4% | -$41.2M -3.0% | -$53.0M -4.2% | -$16.6M -0.8% | -$1.4M -0.1% | $7.9M 0.7% | $12.9M 1.4% | $5.7M 0.7% | $2.0M 0.3% | -$2.4M -0.3% |
| Pretax Income | $272.6M 17.9% | $21.8M 1.6% | $113.0M 8.9% | $193.4M 9.5% | $274.4M 22.1% | $263.7M 23.1% | $234.2M 25.0% | $213.8M 24.9% | $185.8M 23.5% | $433.5M 60.8% |
| Income Tax Expense | $64.9M 4.3% | $5.6M 0.4% | $5.3M 0.4% | $49.9M 2.5% | $44.8M 3.6% | $23.4M 2.0% | $38.0M 4.0% | $20.2M 2.4% | $61.0M 7.7% | $122.4M 17.2% |
| Net Income | -$151.5M -9.9% | -$304.9M -21.9% | $81.5M 6.4% | $143.5M 7.0% | $229.6M 18.5% | $240.3M 21.0% | $196.2M 20.9% | $193.5M 22.5% | $124.8M 15.8% | $311.1M 43.6% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.83 | $-5.72 | $1.54 | $2.68 | $4.16 | $4.39 | $3.67 | $3.70 | $2.42 | $6.28 |
| EPS (Diluted) | $-2.80 | $-5.60 | $1.51 | $2.60 | $3.98 | $4.14 | $3.44 | $3.45 | $2.23 | $5.85 |
| Weighted Avg Shares (Basic) | 53.6M | 53.3M | 52.8M | 53.6M | 55.2M | 54.7M | 53.4M | 52.3M | 51.5M | 49.5M |
| Weighted Avg Shares (Diluted) | 54.2M | 54.4M | 54.1M | 55.2M | 57.7M | 58.0M | 57.1M | 56.0M | 55.9M | 53.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81 · book equity (no price)
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $364M buybacks = $364M returned on $198M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $152M covers the $6M due within a year 24.2× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-01-03 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~6.3% on $524M of debt.
Cash of $152M fully covers short-term debt of $6M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
No current price collected.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 41.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 33.0 | 32.9 | 35.0 | 34.8 | 48.0 | 40.0 | 43.1 | 38.1 |
| Gross Profit | 67.0 | 67.1 | 65.0 | 65.2 | 52.0 | 60.0 | 56.9 | 61.9 |
| R&D | 9.4 | 9.9 | 10.4 | 11.1 | 9.4 | 10.2 | 13.1 | 8.3 |
| SG&A | 33.3 | 33.6 | 32.3 | 31.9 | 32.3 | 35.4 | 39.3 | 33.1 |
| Operating Income | 24.2 | 23.6 | 22.4 | 22.3 | 10.3 | 13.0 | 4.5 | 20.3 |
| Income Tax | 2.4 | 4.0 | 2.0 | 3.6 | 2.5 | 0.4 | 0.4 | 4.3 |
| Net Income | 22.5 | 20.9 | 21.0 | 18.5 | 7.0 | 6.4 | -21.9 | -9.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MASI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.